Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03215030 · OUTCOME

Part 3: Percentage of Participants With Neutralizing Antibodies (NAb) at Any Scheduled and Unscheduled Post-Baseline Visit

A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma · Source last updated 2026-01-29

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
Not reported
Time frame
Up to 20.5 months in Part 3

What was measured

Percentages were rounded off to the nearest decimal.

Analysis population: Immunogenicity-Evaluable Set Analysis included participants with a baseline assessment and at least 1 post-baseline immunogenicity assessment. Overall number of participants analyzed is the number of participants with data available for analyses.

Groups in this outcome

Part 3 (Dose Extension): Modakafusp Alfa 120 mg

Participants received modakafusp alfa 120 mg, infusion, IV, Q4W, for each 28-day treatment cycle until disease progression or treatment discontinuation.

Part 3 (Dose Extension): Modakafusp Alfa 240 mg

Participants received modakafusp alfa 240 mg, infusion, IV, Q4W, for each 28-day treatment cycle until disease progression or treatment discontinuation.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Part 3 (Dose Extension): Modakafusp Alfa 120 mg65
Part 3 (Dose Extension): Modakafusp Alfa 240 mg65

Reported measurements

Source class 1
Values in percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Part 3 (Dose Extension): Modakafusp Alfa 120 mg47.7Not reportedNot reportedNot reportedNot reported
Part 3 (Dose Extension): Modakafusp Alfa 240 mg44.6Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        47.7
      2. group Id
        OG001
        value
        44.6
denoms
  1. counts
    1. group Id
      OG000
      value
      65
    2. group Id
      OG001
      value
      65
    units
    Participants
description
Percentages were rounded off to the nearest decimal.
groups
  1. description
    Participants received modakafusp alfa 120 mg, infusion, IV, Q4W, for each 28-day treatment cycle until disease progression or treatment discontinuation.
    id
    OG000
    title
    Part 3 (Dose Extension): Modakafusp Alfa 120 mg
  2. description
    Participants received modakafusp alfa 240 mg, infusion, IV, Q4W, for each 28-day treatment cycle until disease progression or treatment discontinuation.
    id
    OG001
    title
    Part 3 (Dose Extension): Modakafusp Alfa 240 mg
param Type
NUMBER
population Description
Immunogenicity-Evaluable Set Analysis included participants with a baseline assessment and at least 1 post-baseline immunogenicity assessment. Overall number of participants analyzed is the number of participants with data available for analyses.
reporting Status
POSTED
time Frame
Up to 20.5 months in Part 3
title
Part 3: Percentage of Participants With Neutralizing Antibodies (NAb) at Any Scheduled and Unscheduled Post-Baseline Visit
type
SECONDARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice